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Abstract
Background—We have reported that intermediate repeat lengths of the C9ORF72 repeat are a
risk factor for Parkinson Disease (PD) in a clinically- diagnosed dataset. As 10-25% of clinically
diagnosed PD have different diagnoses upon autopsy, we hypothesized this may reflect phenotypic
heterogeneity or concomitant pathology of other neurodegenerative disorders.
Methods—We screened 488 autopsy-confirmed PD cases for the expansion haplotype tag,
rs3849942T. In 196 identified haplotype carriers, the C9ORF72 repeat was genotyped using the
repeat-primed PCR assay.
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Results—No larger (intermediate or expanded) repeats were found in these autopsy-confirmed
PD samples. This absence of larger repeats is significantly different from the frequency in
clinically-diagnosed datasets (p=0.002).
Conclusions—Our results suggest that expanded or intermediate C9ORF72 repeats in
clinically-diagnosed PD or Parkinsonism might be an indication of heterogeneity in clinically-
diagnosed PD cases. Further studies are needed to elucidate the potential contribution of the
C9ORF72 repeat to autopsy-confirmed PD.
Keywords
autopsy confirmed; Parkinson Disease; C9ORF72 repeat; parkinsonism
Introduction
Parkinson disease (PD) is a neurodegenerative movement disorder that affects
approximately 4-5% of the population at 85 years and older (1). Diagnosis of PD requires at
least two out of the three cardinal symptoms of bradykinesia, rigidity and tremor, and is
often accompanied by postural instability. Parkinson-plus syndromes such as progressive
supranuclear palsy (PSP), multiple system atrophy (MSA) and corticobasal syndrome (CBS)
share symptoms with PD of akinetic rigidity, though each supplemented with disease
specific symptoms (e.g. PSP; supranuclear ophthalmoplegia / MSA; dysautonomia / CBS;
dystonia). In addition, several other neurodegenerative disorders display symptom overlap
with PD, such as amyotrophic lateral sclerosis (ALS), frontotemporal dementia with
Parkinsonism (FTDP), dementia with Lewy bodies (DLB) and Alzheimer disease (AD).
Thus it is not surprising that up to 25% of clinically-diagnosed PD cases have one of these
other disorders identified by neuropathologic evaluation (2). This is true even when the
patients are examined by an experienced movement disorder specialist.
In the last two years, carriers of large (> 30 repeats) or intermediate (20-30) expansions of a
six base pair repeat in the C9ORF72 gene have been reported to cause different
neurodegenerative disorders. These longer repeats (expanded or intermediate) were initially
reported in ALS (20-40%; (3, 4, 19)) and FTD families (10-25%, (3, 4, 20)) but are also
observed in other neurodegenerative disorders, albeit at much lower frequency (AD; 0.5-1%
out of ~5000 reported, PSP; ~1.5% out of ~200 reported, CBS; ~2% out of ~35 reported)
(5-15). Further, our recent report (16) evaluated intermediate repeat lengths (20-30 copies)
in two independent clinically-diagnosed PD datasets, without known family history of other
neurodegenerative disorders, and provided evidence for association between these
intermediate repeat lengths and increased risk for clinical PD.
Given the known heterogeneity of the neuropathologic diagnoses associated with clinically-
diagnosed PD case series (2), we hypothesized that the presence of intermediate and
expanded C9ORF72 repeats in clinically-diagnosed PD patients reflects this
neuropathological heterogeneity. To test this hypothesis, we set out to genotype a large
group of autopsy-confirmed PD cases, effectively filtering out other Parkinsonian
syndromes.
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A total of 488 individuals with PD were included after evaluation with strict clinical and
pathological criteria. All had an antemortem clinical diagnosis of PD, moderate to severe
neuronal loss in the substantia nigra and presence of Lewy bodies in the substantia nigra or
other areas in the brain upon autopsy. Individuals were excluded if any of the following
existed: a prominent dementia syndrome within one year of diagnosis (17), competing
pathologic features (e.g., PSP rather than PD), or Braak neurofibrillary tangle stage greater
than IV. As ascertainment for most samples was through the initial autopsy, no information
on age-at-onset or family history was available on most individuals. None of the 488
individuals overlap with the previously reported clinically-diagnosed PD dataset (16).
However, samples with over 20 repeat copies from the previously reported dataset (16) were
included as positive controls.
To address the possibility that the repeat length is variable between different tissues within
the same individual, we used DNA extracted from the brain when available (85%), with
blood DNA as the source in the remaining 15%. As the substantia nigra is degraded in PD,
DNA from the frontal cortex was utilized in order to have sufficient material.
Genotyping
TagSNP rs3849942 genotyping—The T allele at SNP rs3849942 is found in 95 percent
of all individuals with greater than eight C9ORF72 repeats, and all individuals with greater
than 20 repeats (16, 18). Thus this SNP was genotyped as a screening step, using a custom
TaqMan® genotyping assay (Life Technologies, Applied Biosystems, USA), to identify an
enriched pool of patients who were appropriate for full C9ORF72 repeat typing.
C9ORF72 repeat-primed PCR—The primers developed by DeJesus-Hernandez et al (4)
were used in the C9ORF72 repeat-primed PCR assay. The PCR cycling program of Renton
et al (3) was modified to achieve more robust results on a Veriti 96-well Fast Thermal
Cycler (Life technologies, Applied Biosytems). A custom PCR cycling program was used
(4min at 94°C; 50 cycles of 1min at 94°C, 1min at 64°C and 2min at 72°C; 10min at 72°C).
Fragment length analysis was performed on an ABI 3730xl genetic analyzer (Life
Technologies, Applied Biosystems), and analyzed using GeneMapper software (version 4.0,
Life technologies, Applied Biosytems).
Statistical Methods
We defined the threshold for ‘larger’ repeat copies as over 20 copies. This value was chosen
as it is the most commonly reported lower limit of ‘intermediate’ C9ORF72 repeats (3, 4, 6,
12, 13, 16, 19-32). To test for significant difference in frequency between different datasets
we conducted Fisher's exact tests using the a priori threshold of greater than 20 repeat
copies (RCs). P-values of 0.05 or below were considered statistically significant.
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We identified 196 out of 488 cases (~40%) with the T allele at rs3849942, which tags the
repeat expansion haplotype. These individuals, together with the positive controls, were then
typed using the C9ORF72 repeat-primed assay. All positive controls had repeats ≥ 20
repeats, but no carriers were detected with the intermediate (20-30 copies) or expanded
(>30) repeat copy alleles (range of autopsy cases: ≤4-19 RCs). Similar to previous reports,
approximately 92% of the T allele carriers carried over 8 repeat copies (Figure 1).
To determine whether the absence of intermediate repeat carriers in this group is
significantly different from the frequency of repeats in individuals with clinically-diagnosed
PD, we performed a Fisher's exact test using the previously defined threshold of 20 RCs.
Comparing frequencies of intermediate repeat carriers between the previously reported
clinically-diagnosed dataset (14 out of 889) and the present autopsy confirmed dataset
revealed a significant difference between the two groups (one-tailed Fisher's exact test
p=0.002). Alternatively, assuming a true carrier frequency at the lower bound of the 95%
confidence interval in the clinically-diagnosed dataset (~0.8%), we had a chance of > 98%
of seeing at least one carrier in 488 autopsy-confirmed individuals, indicating that we would
have likely seen the intermediate repeat if it existed in the autopsy-confirmed PD cases.
Discussion
We recently described the intermediate sized C9ORF72 repeats (20 to 30 repeats in size) as
a risk factor for PD in two large clinically-diagnosed datasets (16). Only a small number of
large expansions (>30 RC) have been found in PD, suggesting that repeats over 30 copies
are not a common cause of PD (~0.2% out of ~3500 tested). However, additional
intermediate repeat carriers (20 to 30 repeats) have been reported, totaling ~1% of both
intermediate and expanded repeats in clinical PD cases (11-14, 28, 33-37).
The significant absence of intermediate or expanded repeats in our autopsy-confirmed
dataset supports the hypothesis that the presence of intermediate and larger C9ORF72 repeat
expansions in clinically-diagnosed PD might arise from phenotypic heterogeneity. Xi et al
recently reported nominal association with PD and the 10-repeat allele, which would not
survive multiple testing thresholds.
Interestingly, positive family histories for other clinical neurodegenerative disorders
(including ALS and FTD) have been observed in some of the C9ORF72 positive PD/
parkinsonism families (11, 12, 33, 34), though this is not addressed in all reports. Besides
phenotypic heterogeneity in the PD patients, these observations might also suggest possible
concomitant diseases in these families. Patients with symptoms reminiscent of Parkinson-
plus syndromes, dementia within one year of PD onset, or positive family history of FTD
were excluded from the previously reported clinically-diagnosed dataset. Though not
specifically ascertained in this dataset, identification of positive family history of ALS by
the examiner sufficed for exclusion.
The hypothesis of concomitant pathologies seems to be supported by another report on
C9ORF72 in autopsy confirmed PD (34). The authors observed one carrier of the C9ORF72
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expansion (out of 377 patients with Lewy body positive α-synucleinopathy). As they did not
use any exclusion criteria, the neuropathologic evaluation in this individual also showed
TDP-43 pathology with frontotemporal lobar degeneration features. In combination with the
described family history for ALS, it suggests the clinically diagnosed PD patient may also
have had subclinical FTD.
In addition, the hypothesis of an underlying concomitant pathology might also be relevant to
the control individuals that were reported to carry the C9ORF72 repeat expansion or
intermediate length repeat copies (3, 4, 6, 19-26). Recently, clinical controls have been
shown to present with some measure of “disease”-associated change upon autopsy (38),
allowing for the possibility that the asymptomatic intermediate repeat copy carriers will still
present with pathological indications of disease. This concept gets some support from our
analyses in the clinically-diagnosed datasets (16), where we included only controls with an
age-at-exam higher than 60 years. With this threshold we wanted to reduce the chance of
including preclinical individuals. We in fact observed less controls with over 20RCs in this
group than generally reported so far (<0.5% versus 0.5-1%) (3, 4, 6, 19-26).
In conclusion, we observed that expanded or intermediate C9ORF72 repeats are not
associated with stringently selected autopsy confirmed PD. Our findings underscore the
clinical heterogeneity of PD, and support the hypothesis that the presence of C9ORF72
repeats in PD patients may represent this heterogeneity rather than a direct contribution to
PD itself.
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Figure 1. Histogram of autopsy confirmed PD dataset
Histogram of the maximum number of C9ORF72 repeat copies (X-axis) for 196 rs3849942
T positive, autopsy confirmed PD cases.
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